skip to content
5i Free Trial 300x250
Detailed Quote
5i Report
Rating
A-

Review of Knight Therapeutics

APR 01, 2017 - Pharmaceutical company focused on later stage commercialization of drugs. Lots of cash on the balance sheet, strongly performing loans and being one of the only performers in Canadian healthcare justify a rating upgrade to 'A-'.

Download Report
Company Profile
Interactive Chart
Key Ratios
Top Banner 5i Free Trial
Earnings
Analyst Recommendations
5i Recent Questions

Q: Knight, Celestica and Lundin Mining are all trading at close to 1:1 price to book (per the Globe). Is that meaningful at all for any of these companies? Is it a "value" indicator that suggests better days may be ahead? Your thoughts, please. With thanks.

Read Answer Asked by Christopher on December 12, 2017

Q: Cipher is improving and the stock is trending up. With that being said, Knight looks better for the long term if they ever deploy their cash hoard. I currently have a half position in Cipher where a tax loss can be harvested. Take the tax loss and top up my position in Knight while it's down?
Thanks!

Read Answer Asked by WAYNE on December 08, 2017

Q: I have been watching CZO CLR GUD NLN PLI and GPS for some time and I am considering buying into some of these Companies at these current low prices. I have 2 questions. a) Are the fundamentals sound?? and b) How would you rank them for mid term growth. Thanks for your considered opinion

Read Answer Asked by Bob on December 08, 2017
Insiders
https://research-5iresearch.lpages.co/free-trial-5i-research-5i-blog/
Share Information
News and Media